Abstract
The escalating prevalence of multidrug resistance (MDR) represents not merely a medical challenge, but a systemic shortcoming in our current antimicrobial paradigms. Central to this crisis are biofilms, the structured microbial communities that not only exhibit intrinsic resistance to antibiotics but also facilitate the persistence of dormant cells and the horizontal transfer of resistance genes. While emerging natural and synthetic antimicrobial agents offer potential avenues for intervention, their effectiveness is often limited by issues such as poor bioavailability, toxicity, and production scalability. To overcome these limitations, the field must shift from incremental refinements to transformative strategies. Promising approaches include electrochemical biofilm disruption, phage-antibiotic synergistic therapies, nanoparticle-mediated delivery systems, CRISPR-based genome editing, natural quorum sensing inhibitors, and the application of next-generation probiotics. However, scientific innovation alone is insufficient. A comprehensive response must also encompass policy reform: implementing strict regulations on antibiotic usage in agriculture, incentivizing the development and adoption of rapid diagnostic tools, and adapting clinical trial designs to support the evaluation of combinatorial and multimodal therapies. Addressing biofilm-associated MDR requires a radical, multidisciplinary approach to effectively counter this growing global threat.
1 Introduction
Multidrug resistance (MDR) has transcended the boundaries of a conventional public health issue and now poses a profound existential threat to global healthcare systems and economic stability. With an estimated economic burden projected to reach $100 trillion by 2050 (Haruna et al., 2024), the magnitude of this crisis demands immediate and coordinated international action. Despite these alarming forecasts, current response strategies remain insufficient, often rooted in incremental measures that fail to address the scale and urgency of the problem. Healthcare systems continue to be overwhelmed by MDR pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant Enterobacteriaceae (CRE), which impose significant financial and clinical burdens (Nelson et al., 2021). Simultaneously, unregulated antibiotic use in agriculture continues to accelerate the emergence of resistant strains, undermining both human and animal health. To counter this trajectory, transformative solutions are imperative. This includes substantial government investment in pioneering antimicrobial research, the deployment of AI-enabled surveillance systems in healthcare settings to track resistance patterns in real time, and the advancement of cross-sectoral, multidisciplinary interventions. Critically, MDR must now be recognized as a national and global security threat, given its potential to destabilize food systems, compromise surgical safety, and render modern medical procedures ineffective.
Biofilms, structured microbial communities encased in a self-produced extracellular matrix, are a major contributor to antimicrobial resistance (Safini et al., 2024). These complex aggregates protect bacteria from antibiotics, immune responses, and environmental stresses, making infections chronic and difficult to treat. The rise of MDR pathogens, particularly in hospital-acquired infections, underscores the urgent need for innovative antibiofilm strategies. This article evaluates current trends in combating biofilm-associated MDR, focusing on natural and synthetic compounds, as well as multidisciplinary solutions.
2 The role of biofilms in multidrug resistance
Biofilms play a uniquely pivotal role in multidrug resistance (MDR), functioning as highly evolved microbial survival systems that integrate physical, physiological, and genetic defenses into a robust and adaptive architecture (Figure 1). Unlike singular resistance mechanisms such as efflux pumps or enzymatic drug inactivation, biofilms form a complex extracellular matrix composed of polysaccharides, proteins, nucleic acids, and lipids (Yaacob et al., 2021; Kamaruzzaman et al., 2022; Johari et al., 2023; Hamdan et al., 2024; Syaida et al., 2025). This matrix is not merely a passive barrier; it constitutes a dynamic microenvironment capable of modulating external stresses and shielding resident pathogens from antimicrobial agents. One of the most overlooked aspects of biofilm resilience is its metabolic heterogeneity, which facilitates the formation of dormant persister cells, phenotypically tolerant subpopulations that remain unaffected by antibiotics targeting metabolically active cells (Sadiq et al., 2017). Additionally, gradients of oxygen, nutrients, and pH within the biofilm (Sønderholm et al., 2017) create micro-niches that further compromise antimicrobial efficacy. Compounding this issue, the dense structural organization of biofilms accelerates horizontal gene transfer (HGT) (Li et al., 2018), transforming these communities into hotspots for the dissemination of resistance genes. Importantly, biofilm-associated resistance is not solely a function of genetic mutation but rather a complex tolerance phenotype that merges structural fortification with physiological plasticity. This enables pathogens to persist on medical devices and within chronic infections, even when in vitro tests suggest susceptibility. Such multifaceted defense mechanisms constitute a form of microbial warfare that challenges conventional treatment paradigms. As such, effective therapeutic strategies must include targeted approaches aimed at disrupting the biofilm matrix, reactivating dormant cells, and inhibiting HGT to counteract this formidable clinical threat.
FIGURE 1
3 Natural compounds: harnessing nature’s arsenal
Natural products represent some of the most promising and underexploited agents in the fight against persistent biofilm-associated infections. Far from being mere alternative therapies, these compounds exhibit intricate multitarget mechanisms that can outmaneuver conventional antibiotics. Phytochemicals such as curcumin, quercetin, and berberine have demonstrated potent quorum sensing (QS) inhibitory activity, disrupting bacterial communication networks and suppressing the biosynthesis of the extracellular matrix (Banerjee et al., 2024). Similarly, essential oils including cinnamaldehyde and eugenol exhibit dual functionality, penetrating biofilm structures while compromising the integrity of multidrug-resistant (MDR) bacterial membranes (Purkait et al., 2020). Particularly noteworthy are enzymatic agents such as Dispersin B and DNase I, which selectively degrade structural components of the biofilm matrix, effectively dismantling its protective barrier (Waryah et al., 2017). Additionally, bacteriophages, nature’s highly evolved antimicrobial agents, have demonstrated the ability to penetrate and lyse bacterial cells within biofilms and exhibit synergistic effects when used in combination with antibiotics (Grygiel et al., 2024). Despite their therapeutic potential, the clinical application of natural products remains limited, largely due to challenges including variability in raw materials, poor bioavailability, and a regulatory environment that heavily favors synthetic compounds. Overcoming these barriers will require a paradigm shift: the adoption of standardized extraction protocols augmented by artificial intelligence, the development of nanocarriers for targeted delivery, and the design of robust clinical trials capable of evaluating combinatorial natural product-based therapies. To effectively address the global burden of biofilm-mediated infections, it is imperative that natural products be repositioned not as adjunctive or alternative options, but as primary, scientifically validated therapeutic tools within our antimicrobial arsenal.
4 Synthetic compounds and nanomaterials
Synthetic strategies to combat biofilms offer a high degree of precision and innovation, addressing many of the inherent limitations of conventional antibiotics. Among the most promising approaches are synthetic quorum sensing (QS) inhibitors, such as acyl homoserine lactone (AHL) analogs, which disrupt bacterial communication pathways without inducing the selective pressures that often drive antimicrobial resistance (Majik et al., 2020). These interventions represent a significant paradigm shift in biofilm control, targeting microbial coordination rather than viability. Engineered antimicrobial peptides (AMPs) and their synthetic analogs, peptoids, are emerging as potent anti-biofilm agents due to their ability to penetrate dense biofilm matrices and eliminate persister cells through dual mechanisms involving membrane disruption and intracellular targeting (Stojowska-Swędrzyńska et al., 2023). Equally promising are nanomaterials such as silver, zinc oxide, and graphene-based nanoparticles, which exert multi-faceted antimicrobial activity through the generation of reactive oxygen species (ROS) and direct physical damage to bacterial membranes (Yakup et al., 2024; Yusri et al., 2024). In addition, smart surface coatings on medical devices and implants, designed to resist bacterial adhesion and actively prevent biofilm formation, represent a proactive avenue for reducing device-associated infections (Li et al., 2020). These materials integrate antimicrobial functionality with biocompatibility, offering significant potential in clinical settings. Nonetheless, the widespread application of synthetic strategies must be accompanied by rigorous evaluation of biocompatibility and long-term toxicity, particularly in the context of nanomaterial exposure. Investment in adaptive molecular design and evolution is critical to preempt emerging resistance. Equally important is the development of forward-looking regulatory frameworks that balance the need for innovation with patient safety. If developed and deployed responsibly, synthetic solutions have the potential to revolutionize our approach to biofilm-related infections, providing robust, targeted, and scalable tools in the ongoing battle against antimicrobial resistance.
5 Multidisciplinary and AI-driven approaches: the future of antibiofilm therapy
The complex, multicellular nature of biofilms demands integrated therapeutic strategies, as single-mode interventions often fail due to bacterial adaptability and biofilm resilience. Phage-antibiotic synergy (PAS) exemplifies a promising combinatorial approach, wherein bacteriophages lyse biofilm structures and sensitize embedded bacteria (Chaudhry et al., 2017), allowing antibiotics to penetrate and act more effectively, though phage resistance and narrow host specificity remain challenges. Electrochemical disruption, leveraging bioelectric effects to destabilize the extracellular polymeric matrix, offers a non-chemical means to weaken biofilms (Czerwińska-Główka and Krukiewicz, 2020), but its clinical translation requires optimization for tissue-specific applications. Probiotics and microbiome engineering present a biologically nuanced strategy, where commensal bacteria competitively exclude pathogens and secrete secondary metabolites (Torres Salazar et al., 2021), however, strain selection and ecological stability in diverse host environments are critical hurdles. Meanwhile, clustered regularly interspaced palindromic repeats (CRISPR)-based antimicrobials could revolutionize precision therapy by selectively targeting resistance genes or virulence factors in biofilm communities (De la Fuente-Núñez and Lu, 2017), yet delivery mechanisms and off-target effects pose significant barriers to implementation. Collectively, these multimodal approaches highlight the necessity of tailored, context-dependent solutions that address biofilm heterogeneity while mitigating resistance risks.
A synergistic integration of diverse antibiofilm strategies holds the potential to significantly enhance therapeutic efficacy by leveraging complementary mechanisms of action (Figure 2). For instance, initial electrochemical disruption could compromise the structural integrity of the biofilm matrix, thereby enhancing the penetration and activity of downstream agents such as phage-antibiotic synergy (PAS) systems and graphene-based nanoparticles. These agents can effectively lyse embedded bacteria and sensitize residual populations to both conventional antibiotics and natural quorum sensing inhibitors. Concurrently, CRISPR-based antimicrobials could be employed to selectively target and eliminate resistant or hypervirulent strains, thereby minimizing the risk of regrowth and recurrence. In parallel, the strategic introduction of probiotics may serve to competitively exclude pathogenic species and establish a microenvironment that is antagonistic to biofilm reformation. Metabolites produced by these beneficial microbes could further reinforce the disruption of the biofilm and sustain long-term suppression of pathogenic colonization. This multi-layered, sequential approach enables intervention at various stages of the biofilm lifecycle—structural, genetic, and ecological—offering a comprehensive and adaptable strategy. By exploiting the unique strengths of each modality while offsetting their individual limitations, such a multidisciplinary framework may not only improve clinical outcomes but also reduce the likelihood of resistance development over time.
FIGURE 2
The proposed combinatorial approach demonstrates strong scientific potential for enhancing antibiofilm efficacy by employing sequential and complementary mechanisms to disrupt, eradicate, and prevent the regrowth of biofilm communities. However, several critical challenges must be addressed to ensure their safe and effective implementation. First, electrochemical parameters require precise calibration to avoid collateral damage to host tissues and resident microbiota. Second, compatibility between bacteriophages and CRISPR-based antimicrobials must be carefully evaluated to prevent unintended off-target gene editing in commensal organisms. Third, the delivery efficiency of phages, antibiotics, natural quorum sensing inhibitors, and graphene-based nanoparticles is contingent upon the degree of biofilm porosity following disruption, an aspect complicated by the inherent structural heterogeneity of biofilms, which can result in uneven drug distribution and residual resistance niches. Finally, the selection of probiotic strains must be strategically guided to prevent antagonistic interactions with phages or antibiotics, thereby maintaining ecological balance and therapeutic synergy. Deploying antibiofilm strategies across diverse environments requires tailored optimization, as factors like temperature, pH, UV exposure, and salinity can significantly influence efficacy. For instance, enzymatic biofilm disruptors may denature at extreme temperatures, while nanoparticle stability can vary with ionic strength in saline conditions (Chopada et al., 2025; Jiang et al., 2025). When optimized, this multidisciplinary strategy offers significant advantages over monotherapies by simultaneously dismantling biofilm architecture, eliminating bacterial populations, suppressing resistance mechanisms, and promoting microbiome stability. Rigorous preclinical evaluation is essential to validate the efficacy and safety of this approach across diverse infection models. Notably, Morrisette et al. (2020) suggest that such combination therapies may enable reduced antibiotic dosages, thereby minimizing selective pressure for resistance. Similarly, prior studies advocate multi-targeted or combinatorial regimens as more effective strategies for overcoming the resilience of biofilm-associated infections (Koo et al., 2017; Ranall et al., 2012). Emerging technologies such as stimuli-responsive drug delivery systems, metal-organic frameworks, and hydrogel-based carriers further enhance the prospects of this integrated approach by improving localized delivery, bioavailability, and controlled release (Sikder et al., 2021). Taken together, these innovative strategies mark a pivotal evolution in antimicrobial design and deployment, offering a compelling path forward in addressing the escalating global crisis of antibiotic-resistant infections.
Artificial intelligence (AI) is revolutionizing the development and optimization of multimodal antibiofilm strategies by enabling data-driven decision-making at multiple levels. According to Fagbemi et al. (2025), AI tools can significantly enhance the development of antibiofilm strategies by analyzing vast datasets to predict effective drug combinations, optimize treatment sequences, and identify novel biofilm-disrupting targets. AI-powered systems can optimize antibiotic use by recommending effective treatments based on patient data and local resistance patterns, while also accelerating drug discovery (Branda and Scarpa, 2024). AI-driven approaches such as deep learning can analyze genomic, proteomic, and metabolomic data to pinpoint key biofilm-related genes or vulnerable metabolic pathways for targeted interventions (Yetgin, 2025). Additionally, AI-driven approaches enable rapid screening of parameters to discover optimal nanoparticles configurations for specific therapeutic needs (Kapoor et al., 2024). However, challenges include the need for high-quality, standardized datasets, model interpretability, and real-world validation to ensure clinical applicability. Integrating AI with experimental and clinical data will be crucial for accelerating the translation of predictive insights into effective antibiofilm therapies.
6 Conclusion
To effectively confront biofilm-mediated multidrug resistance (MDR), it is imperative that we move beyond our continued reliance on conventional antibiotics. A paradigm shift in therapeutic strategy is urgently required. While natural compounds offer considerable promise due to their ecological safety and broad-spectrum mechanisms of action, the precision and tunability of synthetic and nanotechnology-based antimicrobials represent a transformative advancement. The future of antibiofilm therapy will likely depend on the strategic integration of these modalities with advanced delivery platforms to enhance efficacy and overcome physiological barriers. However, significant challenges remain. Regulatory complexities, high development costs, and limited scalability continue to impede the clinical translation of these innovations. Despite robust scientific progress, the deployment of next-generation antibiofilm therapies remains constrained by systemic inertia. To bridge the gap between laboratory breakthroughs and real-world applications, we must align scientific innovation with streamlined regulatory frameworks, sustainable funding mechanisms, and policy-level commitment.
Statements
Data availability statement
The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.
Author contributions
MY: Conceptualization, Writing – original draft. MJ: Writing – review and editing. NJ: Writing – review and editing. NN: Writing – original draft. NA: Conceptualization, Writing – review and editing. RS: Conceptualization, Writing – review and editing. NM: Writing – review and editing.
Funding
The author(s) declare that no financial support was received for the research and/or publication of this article.
Acknowledgments
The authors are highly grateful to the Faculty of Applied Sciences, Universiti Teknologi MARA Shah Alam for providing research facility.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that Generative AI was used in the creation of this manuscript. During the preparation of this manuscript, the authors used DeepSeek and Grammarly to reduce spelling and grammar errors. After using these tools, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
BanerjeeD.BiswasP.MazumderK.PalaiS.HossainC. M.KarmakarS.et al (2024). Exploration of phytochemicals as anti-biofilm agents against pathogenic bacteria: their potential and challenges. Infect. Disorders-Drug Targets25. 10.2174/0118715265324950241204182204
2
BrandaF.ScarpaF. (2024). Implications of artificial intelligence in addressing antimicrobial resistance: innovations, global challenges, and healthcare’s future. Antibiotics13 (6), 502. 10.3390/antibiotics13060502
3
ChaudhryW. N.Concepcion-AcevedoJ.ParkT.AndleebS.BullJ. J.LevinB. R. (2017). Synergy and order effects of antibiotics and phages in killing Pseudomonas aeruginosa biofilms. PloS one12 (1), e0168615. 10.1371/journal.pone.0168615
4
ChopadaR.SarwateR.KumarV. (2025). Effect of mild to extreme pH, temperature, and ionic strength on the colloidal stability of differentially capped gold nanoparticles. J. Mol. Struct.1323, 140751. 10.1016/j.molstruc.2024.140751
5
Czerwińska-GłówkaD.KrukiewiczK. (2020). A journey in the complex interactions between electrochemistry and bacteriology: from electroactivity to electromodulation of bacterial biofilms. Bioelectrochemistry131, 107401. 10.1016/j.bioelechem.2019.107401
6
De la Fuente-NúñezC.LuT. K. (2017). CRISPR-Cas9 technology: applications in genome engineering, development of sequence-specific antimicrobials, and future prospects. Integr. Biol.9 (2), 109–122. 10.1039/c6ib00140h
7
FagbemiO. A.EssuahM.UgwuD. C.AjibolaA. B.JuliusS. O.OnyeyiliI. N.et al (2025). Nanobiotechnology-driven innovations for tackling antimicrobial resistance. World J. Biol. Pharm. Health Sci.21 (02), 300–328. 10.30574/wjbphs.2025.21.2.0093
8
GrygielI.BajrakO.WójcickiM.KrusiecK.Jończyk-MatysiakE.GórskiA.et al (2024). Comprehensive approaches to combatting Acinetobacter baumannii biofilms: from biofilm structure to phage-based therapies. Antibiotics13 (11), 1064. 10.3390/antibiotics13111064
9
HamdanH. F.RossE. E. R.JalilM. T. M.HashimM. A.YahyaM. F. Z. R. (2024). Antibiofilm efficacy and mode of action of Etlingera elatior extracts against Staphylococcus aureus. Malays. Appl. Biol.53 (1), 27–34. 10.55230/mabjournal.v53i1.2808
10
HarunaU. A.EshunG.OkesanyaO. J.Mohammed ElhadiY. A.Lucero-prisnoI. I. I. D. E. (2024). Antimicrobial resistance strains the wallet: who pays when we hit the wall?Microbes Infect. Dis.0, 0. 10.21608/mid.2024.309252.2127
11
JiangZ.MaL.LvY.ZhaoH. (2025). Protection of enzymes against heat inactivation by enzyme–polymer conjugates. Macromol. Rapid Commun.46, 2400773. 10.1002/marc.202400773
12
JohariN. A.AazmiM. S.YahyaM. F. Z. R. (2023). FTIR spectroscopic study of inhibition of chloroxylenol-based disinfectant against Salmonella enterica serovar thyphimurium biofilm. Malays. Appl. Biol.52 (2), 97–107. 10.55230/mabjournal.v52i2.2614
13
KamaruzzamanA. N. A.MulokT. E. T. Z.NorN. H. M.YahyaM. F. Z. R. (2022). FTIR spectral changes in Candida albicans biofilm following exposure to antifungals. Malays. Appl. Biol.51 (4), 57–66. 10.55230/mabjournal.v51i4.11
14
KapoorD. U.SharmaJ. B.GandhiS. M.PrajapatiB. G.ThanawuthK.LimmatvapiratS.et al (2024). AI-driven design and optimization of nanoparticle-based drug delivery systems. Sci. Eng. Health Stud., 24010003. 10.69598/sehs.18.24010003
15
KooH.AllanR. N.HowlinR. P.StoodleyP.Hall-StoodleyL. (2017). Targeting microbial biofilms: current and prospective therapeutic strategies. Nat. Rev. Microbiol.15 (12), 740–755. 10.1038/nrmicro.2017.99
16
LiB.QiuY.ZhangJ.HuangX.ShiH.YinH. (2018). Real-time study of rapid spread of antibiotic resistance plasmid in biofilm using microfluidics. Environ. Sci. and Technol.52 (19), 11132–11141. 10.1021/acs.est.8b03281
17
LiM.AveyardJ.FlemingG.CurranJ. M.McBrideF.RavalR.et al (2020). Nitric oxide releasing titanium surfaces for antimicrobial bone-integrating orthopedic implants. ACS Appl. Mater. and interfaces12 (20), 22433–22443. 10.1021/acsami.0c00871
18
MajikM. S.GawasU. B.MandrekarV. K. (2020). Next generation quorum sensing inhibitors: accounts on structure activity relationship studies and biological activities. Bioorg. and Med. Chem.28 (21), 115728. 10.1016/j.bmc.2020.115728
19
MorrisetteT.KebriaeiR.LevK. L.MoralesS.RybakM. J. (2020). Bacteriophage therapeutics: a primer for Clinicians on phage‐antibiotic combinations. J. Hum. Pharmacol. Drug Ther.40 (2), 153–168. 10.1002/phar.2358
20
NelsonR. E.HatfieldK. M.WolfordH.SamoreM. H.ScottR. D.ReddyS. C.et al (2021). National estimates of healthcare costs associated with multidrug-resistant bacterial infections among hospitalized patients in the United States. Clin. Infect. Dis.72, 17–26. 10.1093/cid/ciaa1581
21
PurkaitS.BhattacharyaA.BagA.ChattopadhyayR. R. (2020). Evaluation of antibiofilm efficacy of essential oil components β‐caryophyllene, cinnamaldehyde and eugenol alone and in combination against biofilm formation and preformed biofilms of Listeria monocytogenes and Salmonella typhimurium. Lett. Appl. Microbiol.71 (2), 195–202. 10.1111/lam.13308
22
RanallM. V.ButlerM. S.BlaskovichM. A.CooperM. A. (2012). Resolving biofilm infections: current therapy and drug discovery strategies. Curr. drug targets13 (11), 1375–1385. 10.2174/138945012803530251
23
SadiqF. A.FlintS.LiY.OuK.YuanL.HeG. Q. (2017). Phenotypic and genetic heterogeneity within biofilms with particular emphasis on persistence and antimicrobial tolerance. Future Microbiol.12 (12), 1087–1107. 10.2217/fmb-2017-0042
24
SafiniI. N. M.ZakariaN. F. S.SaadM. I. H.YahyaM. F. Z.JamilN. M. (2024). Understanding bacterial persistence under antibiotic pressure: a review. Sci. Lett.18 (2), 56–69.
25
SikderA.ChaudhuriA.MondalS.SinghN. P. (2021). Recent advances on stimuli-responsive combination therapy against multidrug-resistant bacteria and biofilm. ACS Appl. Bio Mater.4 (6), 4667–4683. 10.1021/acsabm.1c00150
26
SønderholmM.BjarnsholtT.AlhedeM.KolpenM.JensenP. Ø.KühlM.et al (2017). The consequences of being in an infectious biofilm: microenvironmental conditions governing antibiotic tolerance. Int. J. Mol. Sci.18 (12), 2688. 10.3390/ijms18122688
27
Stojowska-SwędrzyńskaK.Kuczyńska-WiśnikD.LaskowskaE. (2023). New strategies to kill metabolically-dormant cells directly bypassing the need for active cellular processes. Antibiotics12 (6), 1044. 10.3390/antibiotics12061044
28
SyaidaA. A. R.YusofM. I. M.JesseF. F. A.MajidN. A. M.YahyaM. F. Z. R. (2025). Structural and proteomic insights into the antibiofilm efficacy of DMSO on Corynebacterium pseudotuberculosis. Asia Pac. J. Mol. Biol. Biotechnol.33 (1), 45–58. 10.35118/apjmbb.2025.033.1.06
29
Torres SalazarB. O.HeilbronnerS.PeschelA.KrismerB. (2021). Secondary metabolites governing microbiome interaction of staphylococcal pathogens and commensals. Microb. Physiol.31 (3), 198–216. 10.1159/000517082
30
WaryahC. B.WellsK.UlluwishewaD.Chen-TanN.Gogoi-TiwariJ.RavensdaleJ.et al (2017). In vitro antimicrobial efficacy of tobramycin against Staphylococcus aureus biofilms in combination with or without DNase I And/Or dispersin B: a preliminary investigation. Microb. Drug Resist.23 (3), 384–390. 10.1089/mdr.2016.0100
31
YaacobM. F.MurataA.NorN. H. M.JesseF. F. A.YahyaM. F. Z. R. (2021). Biochemical composition, morphology and antimicrobial susceptibility pattern of Corynebacterium pseudotuberculosis biofilm. J. King Saud University-Science33 (1), 101225. 10.1016/j.jksus.2020.10.022
32
YakupN. F.NorN. H. M.MahatM. M.SiburianR.YahyaM. F. Z. R. (2024). “Unveiling the antibiofilm arsenal: a mini review on nanoparticles’ mechanisms and efficacy in biofilm inhibition,” in International conference on science technology and social sciences–physics, material and industrial technology (ICONSTAS-PMIT 2023) (Springer Nature), 177–185.
33
YetginA. (2025). Revolutionizing multi‐omics analysis with artificial intelligence and data processing. Quant. Biol.13 (3), e70002. 10.1002/qub2.70002
34
YusriM. H.NorN. H. M.MahatM. M.SiburianR.YahyaM. F. Z. R. (2024). “Insights into antibiofilm mode of actions of natural and synthetic polymers: a mini review,” in Proceedings of the international conference on science technology and social sciences-physics, material and industrial technology (ICONSTAS-PMIT 2023) (Springer Nature), 134.
Summary
Keywords
biofilms, multidrug resistance, antibiotics, antibiofilm activity, natural antimicrobials, synthetic antimicrobials, nanoparticles, probiotics
Citation
Yahya MFZR, Jalil MTM, Jamil NM, Nor NHM, Alhajj N, Siburian R and Majid NA (2025) Biofilms and multidrug resistance: an emerging crisis and the need for multidisciplinary interventions. Front. Bioeng. Biotechnol. 13:1625356. doi: 10.3389/fbioe.2025.1625356
Received
08 May 2025
Accepted
17 June 2025
Published
25 June 2025
Volume
13 - 2025
Edited by
Dong Yu Zhu, Guangdong University of Technology, China
Reviewed by
Shengwei Sun, Royal Institute of Technology, Sweden
Updates
Copyright
© 2025 Yahya, Jalil, Jamil, Nor, Alhajj, Siburian and Majid.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Mohd Fakharul Zaman Raja Yahya, fakharulzaman@uitm.edu.my
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.